Location
MR6 G526
Lab
MR6 G716A/B
P3 Systems Biology Lab LinkedIn Google Scholar

About

Dr. B. Bishal Paudel a systems biologist working at the interface of cancer biology and computational biology with research focused on understanding how dysfunctional biochemical signaling arise, how dysregulated signaling leads to emergent cancer phenotypes, and how those states can be engineered for desired outcomes.

Dr. Paudel's research uses a systems bioengineering approach to investigate how aberrant signaling leads to distinct metabolic and epigenetic states, and to devise strategies for therapeutic reprogramming. P3SystemsBiology lab is interested in two main research areas: (1) network-level regulation of metabolic heterogeneity and (2) oncogene-induced alterations in the epigenome and cancer phenotypes. He integrates bioengineering, mechanistic and statistical modeling with single-cell and population-level experiments to identify metabolic vulnerabilities and drivers of early cancer progression. 

Education

PhD, Chemical and Physical Biology, Vanderbilt University, 2018

BS, Chemistry, Maths-Physics, The College of Idaho, 2011

Research Interests

Systems Biochemistry
Pharmacology
Tumor Metabolism
Bioengineering
Metabolic Reprogramming

Selected Publications

Proinflammation characterizes better risk older AML patients in ECOG-ACRIN Cancer Research Group’s clinical trial E3999 - Accepted in Leukemia (2026) Neelamraju Y, Rapaport F, Gandara JA, Paudel BB, Dewolf S, Dunham N, Fan H, Lee T, Mayo MW, Sheridan C, Sol-Church K, Solga MD, Wang L, Cripe LD, Dillon R, Kleppe M, Mason CE, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Paietta E, Levine R, Melnick AM, Bekirano
Age-dependent topoisomerase I depletion alters recruitment of rDNA silencing complexes (2025) Power LN, Zawrotna N, Dinda M, Weir AE, Paudel BB, Ghimire O, Kisiel K, Letai CT, Janes KA, Smith JS
Journal of Biological Chemistry
Proteome-wide copy-number estimation from transcriptomics (2024) Sweatt AJ, Griffiths CD, Groves SM, Paudel BB, Wang L, Kashatus DF and Janes KA
Molecular Systems Biology
Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes (2024) Paudel BB, Tan SF, Fox TE, Ung J, Shaw J, Dunton W, Lee I, Sharma A, Viny A, Barth BM, Tallman MS, Cabot M, Garrett-Bakelman FE, Levine RL, Kester M, Claxton D, Feith DJ, Janes KA, Loughran TP
Blood Advances
Nucleocytoplasmic transport of active HER2 causes fractional
escape from the DCIS-like state (2023) Wang L#, Paudel BB#, McKnight RA, Janes KA
Nature Communications
An Integrative Gene Expression and Mathematical Flux-Balance Analysis Identifies Targetable Redox Vulnerabilities in Melanoma Cells (2020) Paudel BB, Lewis JE, Hardeman KN, Hayford CE, Robbins CJ, Stauffer PE, Cordeanu GS, Sherrod SD, McLean JA, Kemp, ML, & Quaranta, V
Cancer Research
Dynamics of drug response informs rational combination regimens (2019) Paudel BB & Quaranta, V.
Science Signaling
Quantifying the synergy of drug combinations with respect to potency and efficacy (2019) Meyer CT#, Wooten DJ#, Paudel BB#, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR & Quaranta V
Cell Systems
Metabolic Plasticity Meets Gene Regulation (2019) Paudel BB & Quaranta, V.
Proceedings of the National Academy of Sciences of the United States of America

Featured Grants & Projects

NIH/NCI Transition Career Development Award (K22)